FY2025 · ended Dec 31, 2025 · Revenue $1.00M, -82.5% YoY · Filed Mar 5, 2026
Shattuck Labs, Inc. (STTK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.0 million and a net loss of $48.8 million. Free cash flow was -$40.0 million. As of Sep 30, 2026 it held $61.8 million in cash and investments and $2.5 million in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-67.72M
-23.4% vs year-ago TTM
Operating cash flow (TTM)
$-49.57M
-1.7% vs year-ago TTM
Free cash flow (TTM)
$-49.76M
-1.9% vs year-ago TTM
EPS (TTM)
$-0.00
+15.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
71.56M
+49.4% vs prior year
Net cash
$59.31M
as of Sep 30, 2026
Operating margin
-5150.8%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- STTK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680367
- Former names
- Shattuck Labs, Inc. (until Nov 5, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $5.7M | $1.7M | $652,000 | $30.0M |
| Operating income | -$51.5M | -$80.6M | -$92.0M | -$103.3M | -$45.3M |
| Net income | -$48.8M | -$75.4M | -$87.3M | -$101.9M | -$45.0M |
| Diluted EPS | -$0.70 | -$1.49 | -$2.05 | -$2.41 | -$1.07 |
| Operating cash flow | -$39.9M | -$60.5M | -$81.2M | -$94.5M | -$57.1M |
| Free cash flow | -$40.0M | -$60.6M | -$81.6M | -$106.1M | -$65.0M |
| Total assets | $91.0M | $91.0M | $159.6M | $205.3M | $298.6M |
| Total liabilities | $8.6M | $11.4M | $14.9M | $29.2M | $26.8M |
| Stockholders' equity | $82.4M | $79.6M | $144.7M | $176.2M | $271.8M |
| Cash and investments | $54.2M | $57.4M | $130.6M | $161.3M | $268.8M |
| Total debt | $2.4M | $3.4M | $4.2M | $4.9M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 11, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 9, 2026 | Jun 8, 2026 |
All 413 Shattuck Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.